RUSNATI, MARCO
 Distribuzione geografica
Continente #
NA - Nord America 14.501
EU - Europa 8.199
AS - Asia 7.639
SA - Sud America 1.367
AF - Africa 185
OC - Oceania 42
Continente sconosciuto - Info sul continente non disponibili 16
Totale 31.949
Nazione #
US - Stati Uniti d'America 14.275
PL - Polonia 3.414
CN - Cina 2.634
SG - Singapore 2.609
UA - Ucraina 1.299
BR - Brasile 1.146
HK - Hong Kong 814
DE - Germania 763
IT - Italia 717
VN - Vietnam 559
FI - Finlandia 451
GB - Regno Unito 376
FR - Francia 375
TR - Turchia 262
IN - India 231
RU - Federazione Russa 230
IE - Irlanda 221
CA - Canada 110
BD - Bangladesh 106
AR - Argentina 82
ID - Indonesia 78
MX - Messico 73
NL - Olanda 72
ZA - Sudafrica 66
IQ - Iraq 59
CZ - Repubblica Ceca 51
JP - Giappone 50
SE - Svezia 48
AU - Australia 40
AT - Austria 36
EC - Ecuador 36
ES - Italia 36
PK - Pakistan 34
MA - Marocco 30
BE - Belgio 26
CO - Colombia 25
KE - Kenya 25
UZ - Uzbekistan 24
CL - Cile 22
IR - Iran 22
VE - Venezuela 20
SA - Arabia Saudita 19
JM - Giamaica 16
AE - Emirati Arabi Uniti 15
JO - Giordania 15
EU - Europa 14
AZ - Azerbaigian 13
IL - Israele 13
LT - Lituania 13
PE - Perù 13
CH - Svizzera 12
KZ - Kazakistan 12
NG - Nigeria 12
EG - Egitto 11
MU - Mauritius 9
MY - Malesia 9
PY - Paraguay 9
PA - Panama 8
UY - Uruguay 8
BG - Bulgaria 7
DZ - Algeria 7
PT - Portogallo 7
TN - Tunisia 7
EE - Estonia 6
KR - Corea 6
LK - Sri Lanka 6
NP - Nepal 6
OM - Oman 6
KG - Kirghizistan 5
LB - Libano 5
LV - Lettonia 5
SN - Senegal 5
TH - Thailandia 5
BO - Bolivia 4
DK - Danimarca 4
DO - Repubblica Dominicana 4
NO - Norvegia 4
TW - Taiwan 4
AL - Albania 3
CY - Cipro 3
ET - Etiopia 3
GR - Grecia 3
HN - Honduras 3
HU - Ungheria 3
MD - Moldavia 3
PH - Filippine 3
PS - Palestinian Territory 3
RO - Romania 3
TT - Trinidad e Tobago 3
AM - Armenia 2
AO - Angola 2
BB - Barbados 2
BH - Bahrain 2
CR - Costa Rica 2
GF - Guiana Francese 2
IS - Islanda 2
SI - Slovenia 2
SV - El Salvador 2
ZW - Zimbabwe 2
A2 - ???statistics.table.value.countryCode.A2??? 1
Totale 31.925
Città #
Warsaw 3.405
Fairfield 1.667
Woodbridge 1.275
Ashburn 1.232
Singapore 1.230
Jacksonville 957
Houston 898
Hong Kong 811
Cambridge 711
Ann Arbor 605
Wilmington 599
Seattle 580
Beijing 561
San Jose 548
Chandler 503
The Dalles 449
Princeton 397
Nanjing 348
New York 297
Dallas 288
Helsinki 244
Los Angeles 221
Dublin 215
Lauterbourg 204
Istanbul 186
Dearborn 154
Ho Chi Minh City 151
Council Bluffs 143
Brescia 132
Nanchang 125
Dong Ket 122
Munich 114
São Paulo 114
Milan 103
Buffalo 99
Moscow 98
Hanoi 97
San Diego 88
San Francisco 88
Des Moines 86
Shenyang 84
Jinan 82
Changsha 80
Hebei 74
Chicago 72
Boardman 71
Redondo Beach 70
Tianjin 68
Jiaxing 65
Lancaster 63
Shanghai 62
London 61
Santa Clara 57
Orem 54
Hangzhou 51
Brooklyn 49
Phoenix 47
Jakarta 46
Kunming 46
Tokyo 44
Toronto 40
Verona 40
Atlanta 38
Johannesburg 36
Rome 36
Guangzhou 35
Rio de Janeiro 34
Augusta 32
San Mateo 32
Porto Alegre 31
Belo Horizonte 30
Chennai 30
Manchester 30
Montreal 29
Zhengzhou 29
Nuremberg 28
Turku 28
Brno 27
Frankfurt am Main 27
Haikou 27
Lanzhou 27
Denver 26
Ningbo 26
Leawood 25
Amsterdam 24
Kocaeli 24
Brussels 23
Mexico City 23
Norwalk 22
Poplar 22
Curitiba 21
Nairobi 21
Olomouc 21
Dhaka 20
Parma 20
Tashkent 20
Boston 19
Brasília 19
Mumbai 19
Salt Lake City 19
Totale 22.471
Nome #
Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. 372
Bridging the past and the future of virology: Surface plasmon resonance as a powerful tool to investigate virus/host interactions. 360
Δ5-Cholenoyl-amino acids as selective and orally available antagonists of the Epheephrin system 316
Heparin/Heparan sulfate proteoglycans glycomic interactome in angiogenesis: biological implications and therapeutical use 315
Antiangiogenic activity of semisynthetic biotechnological heparins: low-molecular-weight-sulfated Escherichia coli K5 polysaccharide derivatives as fibroblast growth factor antagonists. 311
Biological role of immunoglobulin Free light chains interactomes 306
BSA conjugates bearing multiple copies of the basic domain of HIV-1 Tat: prototype for the development of multitarget inhibitors of extracellular Tat 305
Membrane association of peroxiredoxin-2 in red cells is mediated by n-terminal cytoplasmic domain of band 3 301
Blocking the FGF/FGFR system as a "two-compartment" antiangiogenic/antitumor approach in cancer therapy. 299
Activation of Hsp90 Enzymatic Activity and Conformational Dynamics through Rationally Designed Allosteric Ligands 289
Highly Sulfated K5 Escherichia coli Polysaccharide Derivatives Inhibit Respiratory Syncytial Virus Infectivity in Cell Lines and Human Tracheal-Bronchial Histocultures. 288
Speeding Up the Identification of Cystic Fibrosis Transmembrane Conductance Regulator-Targeted Drugs: An Approach Based on Bioinformatics Strategies and Surface Plasmon Resonance 281
Angiogenic growth factors interactome and drug discovery: The contribution of surface plasmon resonance 276
Interaction of fibroblast growth factor-2 (FGF-2) with free gangliosides: biochemical characterization and biological consequences in endothelial cell cultures. 274
Heparan Sulfate Proteoglycans Mediate the Angiogenic Activity of the Vascular Endothelial Growth Factor Receptor-2 Agonist Gremlin. 272
Ruolo dell’eparina e dei proteoglicani eparan solfati nella modulazione dell’angiogenesi indotta dal fattore di crescita basico dei fibroblasti 271
Chemically sulfated Escherichia coli K5 polysaccharide derivatives as extracellular HIV-1 Tat protein antagonists. 270
Inhibition of Non Canonical HIV-1 Tat Secretion Through the Cellular Na+,K+-ATPase Blocks HIV-1 Infection 259
Pradamicin A: a new therapeutic concept for tretment of virus infections with a glycosilated envelope such as human immunodeficiency virus 256
Integrating computational and chemical biology tools in the discovery of antiangiogenic small molecule ligands of FGF2 derived from endogenous inhibitors 254
UniPR1331, a small molecule targeting Eph/ephrin interaction, prolongs survival in glioblastoma and potentiates the effect of antiangiogenic therapy in mice 249
In silico drug repositioning on F508del-CFTR: A proof-of-concept study on the AIFA library 248
A complex of α(6) integrin and E-cadherin drives liver metastasis of colorectal cancer cells through hepatic angiopoietin-like 6. 246
Role of the soluble pattern recognition receptor PTX3 in vascular biology. 245
The AGMA1 poly(amidoamine) inhibits the infectivity of herpes simplex virus in cell lines, in human cervicovaginal histocultures, and in vaginally infected mice 241
The FGF2-binding domain of thrombospondin-1: functional characterization and exploitation to design antiangiogenic compounds 239
Fibroblast growth factors/fibroblast growth factor receptors as targets for the development of anti-angiogenesis strategies. 234
Functionalization of gold surfaces with copoly(DMA-NAS-MAPS) by dip coating: Surface characterization and hybridization tests 231
Sialic acid associated to αvβ3 integrin mediates HIV-1 Tat interaction and endothelial cell proangiogenic activation. 228
Chemoselective surface immbolization of proteins through a cleavable peptide 221
The agmatine-containing poly(Amidoamine) polymer AGMA1 binds cell surface heparan sulfates and prevents attachment of mucosal human papillomaviruses 218
Heparin-mimicking sulfonic acid polymers as multitarget inhibitors of HIV-1 Tat and gp120 proteins 217
Molecular Interaction Studies of HIV-1 Matrix Protein p17 and Heparin: IDENTIFICATION OF THE HEPARIN-BINDING MOTIF OF p17 AS A TARGET FOR THE DEVELOPMENT OF MULTITARGET ANTAGONISTS 213
Integrin {alpha}V{beta}3 as a Target for Blocking HIV-1 Tat-Induced Endothelial Cell Activation In Vitro and Angiogenesis In Vivo. 212
A distinct basic fibroblast growth factor (FGF-2/FGF receptor interaction distinguishes urokinase-type plasminogen activator induction from mitogenicity in endothelial cells 206
Biological activity of substrate-bound basic fibroblast growth factor (FGF2): recruitment of FGF receptor-1 in endothelial cell adhesion contacts. 204
Fibroblast growth factor-2 antagonist and Antiangiogenic activity of long-pentraxin 3-derived synthetic peptides 202
A natural HIV p17 protein variant up-regulates the LMP-1 EBV oncoprotein and promotes the growth of EBV-infected B-lymphocytes: Implications for EBV-driven lymphomagenesis in the HIV setting. 201
A CXCR1 haplotype hampers HIV-1 matrix protein p17 biological activity 201
Basic fibroblast growth factor-induced angiogenic phenotype in mouse endothelium. A study of aortic and microvascular endothelial cell lines. 196
Biologically active synthetic fragments of human basic fibroblast growth factor (bFGF): identification of two Asp-Gly-Arg-containing domains involved in the mitogenic activity of bFGF in endothelial cells. 193
Critical role of gonadal hormones on the genotoxic activity of the hepatocarcinogen DL-ZAMI 1305. 193
Merging colloidal nanoplasmonics and surface plasmon resonance spectroscopy for enhanced profiling of multiple myeloma-derived exosomes 190
The potential of fibroblast growth factor/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis. 189
alphav/beta3 Integrin mediates the cell-adhesive capacity and biological activity of basic fibroblast growth factor (FGF2) in cultured endothelial cells 187
Contribution of vascular endothelial growth factor receptor-2 sialylation to the process of angiogenesis 187
Basic fibroblast growth factor is released from endothelial extracellular matrix in a biologically active form. 184
Exploitation of a novel biosensor based on the full-length human F508del-CFTR with computational studies, biochemical and biological assays for the characterization of a new Lumacaftor/Tezacaftor analogue 183
Basic fibroblast growth factor requires a long-lasting activation of protein kinase C to induce cell proliferation in transformed fetal bovine aortic endothelial cells. 181
Fibroblast growth factors (FGFs) in cancer: FGF traps as a new therapeutic approach 178
Alterations of blood vessel development by endothelial cells overexpressing fibroblast growth factor-2 175
A six-amino acid deletion in basic fibroblast growth factor dissociates its mitogenic activity from its plasminogen activator-inducing capacity. 175
Examining new models for the study of autocrine and paracrine mechanisms of angiogenesis through FGF2-transfected endothelial and tumour cells. 174
Sialic acid as a target for the development of novel antiangiogenic strategies 173
A mutant of basic fibroblast growth factor that has lost the ability to stimulate plasminogen activator synthesis in endothelial cells. 172
Heparin and heparan sulfate proteoglycans promote HIV-1 p17 matrix protein oligomerization: computational, biochemical and biological implications 167
Upregulation of urokinase-type plasminogen activator in squamous cell carcinoma of human larynx 166
Basic fibroblast growth factor expression in endothelial cells: an autocrine role in angiogenesis? 166
Biochemical characterization of EphA2 antagonists with improved physico-chemical properties by cell-based assays and surface plasmon resonance analysis 165
Autocrine role of basic fibroblast growth factor (bFGF) in angiogenesis and angioproliferative diseases 159
Subcellular localization and biological activity of a Mr 18,000 basic fibroblast growth factor: site directed mutagenesis of a putative nuclear translocation sequence 157
Surface functionalization of extracellular vesicle nanoparticles with antibodies: a first study on the protein corona "variable" 155
Simian immunodeficiency virus and human immunodeficiency virus type 1 matrix proteins specify different capabilities to modulate B cell growth. 155
Distinct role of 2-O, N-, and 6-O-sulfate groups of heparin in the formation of the ternary complex with basic fibroblast growth factor and soluble FGF receptor-1 155
Cutting edge: proangiogenic properties of alternatively activated dendritic cells. 155
Basic fibroblast growth factor in ovulatory cycle and postmenopausal human endometrium. 153
HIV-1 matrix protein p17 binds to the IL-8 receptor CXCR1 and shows IL-8-like chemokine activity on monocytes through Rho/ROCK activation 153
Human basic fibroblast growth factor: structure- function relationship of an angiogenic molecule 152
Syndecan-1 increases B-lymphoid cell extravasation in response to HIV-1 Tat via αvβ3/pp60src/pp125FAK pathway 151
Inhibition of Eph/ephrin interaction with the small molecule UniPR500 improves glucose tolerance in healthy and insulin-resistant mice 151
The colloidal side of cell communication. 149
alpha v beta 3 integrin-dependent activation of focal adhesion kinase mediates NF-kB activation and motogenic activity by HIV-1 Tat in endothelial cells 148
Interaction of fibroblast growth factor-2 (FGF-2) with free gangliosides: biochemical characterization and biological consequences in endothelial cell cultures 147
Cell membrane GM1 ganglioside is a functional co-receptor for Fibroblast growth factor-2. 147
Exploiting Surface Plasmon Resonance (SPR) Technology for the Identification of Fibroblast Growth Factor-2 (FGF2) Antagonists Endowed with Antiangiogenic Activity 146
Purification of basic fibroblast growth factor from rat brain: identification of a Mr 22,000 immunoreactive form. 145
The calcium-binding type III repeats domain of thrombospondin-2 binds to fibroblast growth factor 2 (FGF2) 144
A monoclonal antibody to the NH2-terminal region of HuIFN inhibits the antiproliferative activity of the lymphokine without affecting its internalization 143
Biochemical bases of the interaction of the human basic fibroblast growth factor with glycosaminoglycans: new insights from trypsin digestion studies 142
HIV-1 matrix protein p17 promotes angiogenesis via chemokine receptors CXCR1 and CXCR2 142
Fibroblast growth factor-2 in angiogenesis 141
Liver DNA damage by chemical carcinogens: role of thyroid hormones 137
Heparin derivatives as angiogenesis inhibitors 136
Dendritic cell-endothelial cell cross-talk in angiogenesis. 136
Structure-function relationship of basic fibroblast growth factor: site-directed mutagenesis of a putative heparin-binding and receptor-binding region. 136
Polysulfated/sulfonated compounds for the development of drugs at the crossroad of viral infection and oncogenesis 135
Plasmonic exosomes for enhanced monitoring of monoclonal gammopathies 135
Short heparin sequences spaced by glycol-split uronate residues are antagonists of fibroblast growth factor 2 and angiogenesis inhibitors. 134
The Impact of Surface Plasmon Resonance in Virology 134
Fibroblast growth factors and their receptors in hematopoiesis and hematological tumors 133
Targeting fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis 133
Basic fibroblast growth factor overexpression in endothelial cells: an autocrine mechanism for angiogenesis and angioproliferative diseases 132
Pharmacological evaluation of new bioavailable small molecules targeting Eph/ephrin interaction 132
Sulfated K5 Escherichia coli polysaccharide derivatives as wide range inhibitors of genital types of human papillomavirus 131
Modulation of fibroblast growth factor-2 receptor binding, signaling, and mitogenic activity by heparin-mimicking polysulfonated compounds 131
Urokinase-type plasminogen activator overexpression enhances the invasive capacity of endothelial cells. 131
Characterization of a Mr 20,000 basic fibroblast growth factor-like protein secreted by normal and transformed fetal bovine aortic endothelial cells. 131
Internalization of HIV-1 Tat requires cell surface heparan sulfate proteoglycans 130
Multispot, label-free biodetection at a phantom plastic-water interface. 130
Angiogenic phenotype induced by basic fibroblast growth factor transfection in brain microvascular endothelial cells: an in vitro autocrine model of angiogenesis in brain tumors 129
Totale 19.541
Categoria #
all - tutte 130.639
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 130.639


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021905 0 0 0 0 0 0 0 0 0 280 409 216
2021/20221.785 93 423 30 43 24 69 123 119 84 235 141 401
2022/20231.409 219 59 56 93 106 382 9 149 198 18 48 72
2023/20241.549 93 30 137 68 67 235 52 69 403 49 40 306
2024/20253.988 47 23 18 493 356 286 279 125 350 461 948 602
2025/20268.307 824 1.167 829 1.315 805 602 1.301 317 579 568 0 0
Totale 32.381